LATEST NEWS
   
2009, December 31
  D-Pharm (DPRM: TASE) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI
2009, November 9
  D-Pharm Enters into Collaboration with Wanbang Biopharmaceuticals to Increase the Potential Market for its Stroke Drug-Candidate DP-b99.
2009, August 17
  D-Pharm raises NIS 85 Million in rights offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE).
 

 
  
   DP-b99 a new treatment for acute stroke patients – short film English